Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment
Journal
Gut
Date Issued
2020
Author(s)
Chen C.-Y.
Su W.-W.
Tseng K.-C.
Lo C.-C.
Chen J.-J.
Peng C.-Y.
Shih Y.-L.
Yang S.-S.
Huang C.-S.
Huang K.-J.
Chang C.-Y.
Tsai M.-C.
Kao W.-Y.
Chen P.-Y.
Su P.-Y.
Tseng C.-W.
Huang J.-J.
Lee P.-L.
Lai H.-C.
Hsieh T.-Y.
Chang C.-H.
Huang Y.-J.
Lee F.-J.
Chang C.-C.
Abstract
OBJECTIVE: Data regarding the real-world effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) with or without low-dose ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) infection and severe renal impairment (RI) are limited. We evaluated the performance of SOF/VEL with or without low-dose RBV in HCV-infected patients with chronic kidney disease stage 4 or 5. DESIGN: ) in evaluable (EP) and per-protocol populations (PP). The safety profiles were assessed. RESULTS: were attributed to non-virological failures. Among the 20 serious adverse events (AEs), none were judged related to SOF/VEL or RBV. The AEs occurring in ≥10% included fatigue (14.7%), headache (14.1%), nausea (12.6%), insomnia (12.0%) and pruritus (10.5%). None had ≥grade 3 total bilirubin or alanine aminotransferase elevations. CONCLUSION: SOF/VEL with or without low-dose RBV is effective and well-tolerated in HCV-infected patients with severe RI.
SDGs
Publisher
BMJ Publishing Group
Type
journal article